page header

Contents  ·  Introduction  ·  Learning  Objectives  ·  Textbook  ·  Lectures  ·  Procedures  ·  Final Exam  ·  Library  ·  Laboratory  ·  Pharmacy  ·  Imaging  ·  Forms  ·  Videos  ·  About  ·  Contact Us>

Dextran (Dextran 40, Dextran 70, Dextran 75)

Category:

  • Plasma Expanders

Description:

  • Dexran 40: Low molecular weight glucose polymer plasma expander

  • Dextan 70 & 75: High molecular weight glucose polymer plasma expander

Indications:

  • Fluid replacement in certain types of shock if whole blood or blood products not available

  • Priming fluid in pump oxygenators

  • Prophylaxis of venous thrombosis and pulmonary embolism associated with high risk thromboembolic surgeries

  • Improve circulation in sickle cell and MI patients

Contraindications:

  • Allergy to dextran

  • Product is not clear

Precautions:

  • Observe initially for hypersensitivity reactions

  • Heart failure

Adverse Reactions (Side Effects):

  • Urticaria, pulmonary edema

  • Anaphylaxis

Dosage:

Administered via intravenous infusion

  • Dextran 40: 

    • IV INF 10% (contains no preservative; discard unused product)

    • Shock: 

      • Max 2 g/kg (20ml/kg) first 24 hours; 

      • Do not exceed 1 g/kg (10ml/kg) per 24 hours thereafter.  

      • Therapy max 5 days.  

      • Infuse first 500ml rapidly, infuse remaining slowly.

    • Prophylaxis of Venous Thrombosis and Pulmonary Embolism: 

      • On day of surgery, IV INF 10% 50-100g (500-1000ml or approximately 10 ml/kg). 

      • Additional 2-3 days dose 50g (500ml) daily. 

      • Depending on risk, 50g every second or third day up to 2 weeks.

  • Dextran 70/75: 

    • IV INF 6% (contains no preservative; discard unused product)

    • Max 1.2 g/kg (20ml/kg) first 24 hours

    • Additional therapy max 0.6 g/kg (10 ml/kg) daily.  

    • Usual adult dose 30g (500ml).  

    • Rate of infusion should not exceed 0.24g (4ml) per minute.

 


The information contained here is an abbreviated summary. For more detailed and complete information, consult the manufacturer's product information sheets or standard textbooks

Source: Operational Medicine 2001,  Health Care in Military Settings, NAVMED P-5139, May 1, 2001, Bureau of Medicine and Surgery, Department of the Navy, 2300 E Street NW, Washington, D.C., 20372-5300

This information is provided by The Brookside Associates.  The Brookside Associates, LLC. is a private organization, not affiliated with any governmental agency. The opinions presented here are those of the author and do not necessarily represent the opinions of the Brookside Associates or the Department of Defense. The presence of any advertising on these pages does not constitute an endorsement of that product or service by either the US Department of Defense or the Brookside Associates. All material presented here is unclassified.

C. 2009, 2014, All Rights Reserved

brookside associates logo

 

 

 

 

 

 

Advertise on this site